Factors Affecting Early Progress of Cochlear Implant Outcomes in Adults
Launched by COCHLEAR · Feb 23, 2022
Trial Information
Current as of May 08, 2025
Completed
Keywords
ClinConnect Summary
No description provided
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Adult subjects, 18 years or older
- • Subjects unilaterally implanted or bilaterally implanted with at least 6 months separating the two cochlear implantations.
- • Subjects who have been implanted between January 2016 and December 2021.
- • Subjects have received a Nucleus CI: CI512, CI522 or CI532 cochlear implants with non-rotating magnet, or CI600 series equivalent CI612, CI622 and CI632 with rotating magnet and external sound processors CP900 or CP1000 behind-the-ear, or Kanso or Kanso 2 off-the-ear types.
- • Subjects who are fluent in French (language used in the questionnaire and speech tests)
- • Subjects who are not opposed to participating in the study
- • Subjects for who the medical record data is available throughout the defined data search period.
- Exclusion Criteria:
- • Subjects with single-sided deafness (SSD).
- • Subjects who are not affiliated to the French Social Security.
- • Subjects who are under legal protection.
About Cochlear
Cochlear Limited is a global leader in implantable hearing solutions, dedicated to transforming the lives of individuals with hearing loss through innovative technology and comprehensive clinical research. With a strong commitment to advancing auditory rehabilitation, Cochlear conducts rigorous clinical trials aimed at evaluating the safety and efficacy of its products, including cochlear implants and bone conduction devices. The company collaborates with healthcare professionals and research institutions worldwide to ensure that its solutions meet the highest standards of quality and performance, ultimately enhancing patient outcomes and promoting accessibility to hearing health care.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Toulouse, , France
Patients applied
Trial Officials
Mathieu Marx, MD
Principal Investigator
Hôpital Pierre-Paul Riquet
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials